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Role of endothelin as a mitogen in experimental glomerulonephritis in
rats. Recent studies have revealed that endothelin-1 (ET-1) is a potent
mitogen for mesangial cells in vitro. To determine whether ET-1 exerts the
mitogenic action on mesangial cells in vivo, we examined the glomerular
expression of ET-1 and its receptors in a rat model of mesangial
proliferative glomerulonephritis and assessed the effect of a specific
endothelin A (ETA) receptor antagonist, FR139317, on mesangial cell
proliferation in this model. The levels of preproET-i mRNA expression
and ET-1 protein production in glomeruli increased markedly on days 4
and 7 after disease induction, and the levels changed in concordance with
the glomerular cell proliferation. In contrast, the level of ETA receptor
mRNA initially decreased on day 1, and thereafter increased on days 4 and
7. Administration of FR139317 to rats with experimental glomerulone-
phritis induced a significant reduction in mesangial cell proliferation. In
addition, in situ hybridization of preproET-I mRNA and double-immu-
nolabeling of ED-i and OX-7 in a mirror image section revealed that the
principal cells expressing ET-1 in glomeruli were infiltrating macrophages
on day 1, and they were replaced by mesangial cells on day 4. These
findings indicate that ET-i functions as a potent mitogen for mesangial
cells in vivo in an autocrine or paracrine fashion.
Endothelins (ET) are a family of 21 amino acid peptides that
include three distinct isoforms (ET-1, ET-2, and ET-3) [1, 2].
These isopeptides show different biological activities and bind to
at least two subtypes of G protein-coupled receptors. One is ETA
receptor that shows a selective affinity for ET-1 and ET-2, and the
other is ETB receptor that shows a non-selective affinity for three
isopeptides [3—6]. Although endothelin was originally identified as
a potent vasoconstrictor peptide, subsequent studies have re-
vealed that endothelin possesses a wide range of biological
activities in addition to vasoconstrictor action, including regula-
tion of vasomotor tone, neuromodulation and neurotransmission,
Na and water handling in the kidney, and release of pituitary
hormones, atrial natriuretic peptide, renin, and catecholamines [7,
8].
In addition, many in vitro studies have revealed that ET-1 is a
potent mitogen for a variety of cell types [9, 101. In the kidney,
ET-1 is produced by glomerular endothelial cells, mesangial cells,
epithelial cells, and tubular epithelial cells [11—131. ET-1 has also
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been shown to exert a potent mitogenic effect on cultured
mesangial cells as well as on vascular smooth muscle cells,
suggesting that ET-1 acts as a growth factor in the kidney [14, 15].
In contrast to the findings of in vitro studies, the mitogenic action
of ET-1 has not yet been established in vivo. Therefore, we
designed this study to determine whether ET-1 functions as a
mitogen for mesangial cells in vivo and, if so, which glomerular
cells mainly produce ET-1. To answer these questions, we chose
an experimental model of mesangial proliferative glomerulone-
phritis (anti-Thy I UN). This model is relevant to our study
because it causes selective injury and subsequent proliferation of
mesangial cells, and moreover, its similar features, namely me-
sangiolysis and mesangial proliferation, can be observed in many
human renal diseases such as hemolytic-uremic syndrome, renal
transplant rejection, IgA nephropathy, acute glomerulonephritis,
and diabetic nephropathy [16]. In the present study, we examined
the glomerular expression of ET-1 and its receptors in rats with
anti-Thy I GN, and in addition assessed the effect of endothelin
receptor antagonist on mesangial cell proliferation in the same
model.
Methods
Experimental protocol
Experiment I. Male Sprague-Dawley (SD) rats, 6 to 8 weeks old,
were used in the present study. Experimental mesangial prolifer-
ative glomerulonephritis was induced by intravenous administra-
tion of anti-thymocyte serum (ATS), 1 ml/100 g body wt, in SD
rats (anti-Thy 1 GN). ATS was produced by immunizing New
Zealand white rabbits with I X i0 rat thymocytes in complete
Freund's adjuvant, followed by booster administration of 1 >< 106
thymocytes intravenously two and four weeks later [17]. The rats
were divided into the following five groups: (1) normal baseline
rats (day 0) (N = 21); (2—5) rats with anti-Thy 1 GN on 1, 4, 7, and
14 days after disease induction (N = 21 in each group). The rats
were sacrificed for histological examination of kidney tissue and
isolation of glomeruli for both culture and RNA extraction.
Experiment II. The effect of a specific ETA receptor antagonist,
FR139317 (Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan)
[18], on glomerular cell proliferation was investigated in rats with
anti-Thy 1 GN. Anti-Thy 1 GN in SD rats was induced using the
same methods as described in the experiment I. The rats were
divided into the following two groups: (1) rats that were admin-
istered FR139317 at a dose of 10 mg/lOU g body wt daily and
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intraperitoneally from three days before to seven days after ATS
injection (N = 16); (2) control rats that were administered an
equivalent quantity of saline for the same period (N = 16). For
each group of rats, systolic blood pressure was measured before
and on days 4 and 7 after disease induction. The systolic blood
pressure was measured in conscious rats by the tail cuff method.
The rats were sacrificed on day 4 or 7, and the kidneys were
excised for histological examination.
Glomerular culture
The rats were anesthetized intraperitoneally with pentobarhital
sodium 5 mgIlOO g body wt. The kidneys were perfused in situ via
the aorta with phosphate-buffered saline (PBS), pH 7.4 and then
excised. The capsules were removed and then the cortical tissue
was dissected out and minced with a razor blade. Glomeruli were
isolated using the graded sieving technique [19]. The tissue was
passed sequentially through a 150, 112, and 71 jim sieve. intact
glomeruli retained on the 71 jim sieve were removed, washed
three times in PBS, pH 7.4, and centrifuged. All glomerular
preparations used consisted of more than 95% glomeruli with
minimal tubular contamination. Isolated glomeruli were resus-
pended at 5 X i03 glomeruli per milliliter in serum-free and
antibiotic-free Dulbecco's modified Eagle's medium (DMEM)
(GIBCO BRL, Grand island, NY, USA) in six-well multiwell
plates [20, 21]. After a 24-hour incubation, the glomeruli sus-
pended in 1.0 ml of DMEM were quickly homogenized with
Polytron for 15 seconds [21]. The homogenate was centrifuged at
1500 g for five minutes, and the supernatants were removed, and
stored at —20°C until endothelin assay was performed.
Endothelin assay
A 1 ml aliquot of supernatant acidified with trifluoroacetic acid
(TFA) was applied to Spe-C8 column (iT. Baker Inc., Phillips-
burg, NJ, USA) prewashed sequentially with methanol, distilled
water, and 0.1% TFA [22]. The materials adsorbed to the
cartridge were eluted with 2 ml of 60% acetonitrile and 0.1%
TFA, lyophilized, and reconstituted in the assay buffer for radio-
immunoassay (RIA). The assay buffer was 0.01 M phosphate
buffer, pH 7.4, Containing 0.14 M NaCl, 0.01 M EDTA, 0,02 M
glycine, 0.01 M €-aminocaproic acid, 0.001 M sodium azide, 0.1
mglml heat-inactivated human serum albumin, and 0.1% Triton
X-100. The incubation mixture consisted of 0.1 ml of sample or
standard, 0.1 ml of assay buffer, and 0.1 ml of anti-ET-1 serum
(final dilution 1:20000; Peninsula Laboratories, Belmont, CA,
USA). Incubation was carried out at 4°C for 24 hours, followed by
the late addition of 0.05 ml of 1251-ET-1 (Amersham Corp.,
Arlington Heights, IL, USA) and further incubation at 4°C for 48
hours. To separate bound radioactivity from free ligands, 10 jil of
goat anti-rabbit IgG, 1 l of normal rabbit serum, and 5%
polyethylene glycol were added and centrifuged at 2000 g for 30
minutes. The radioactivity in the precipitate was counted in a
y-spectrometer. A standard curve was constructed, and sample
ET-1 values were extrapolated from the standard curve linearized
by a logit-log transformation.
Preparation of cDNA probes
eDNA probes for rat preproET-1 and rat ETB receptor were
kindly provided by Dr. T. Sakurai (Tsukuba University, Ibaraki,
Japan) [23]. eDNA probes for rat ETA receptor and rat glyceral-
dehyde-3-phosphate-dehydrogenase (GAPDH) were prepared
using reverse transcription in combination with polymerase chain
reaction (RT-PCR) as described previously [241.
For the rat ETA receptor gene, the sense primer was 5'-
CAGCAGACAAAAATCACGAC-3' defined by bases 254 to
273, the antisense primer was 5'-AGAAGTAGAATCCAAA-
GAGC-3' defined by bases 817 to 836, according to full-length rat
ETA receptor eDNA [6]. For the rat GAPDH gene, the sense
primer was 5'-TCCCTCAAGATFGTCAGCAA-3' defined by
bases 451 to 470, the antisense primer was 5'-AGATCCA-
CAACGGATACATT-3' defined by bases 739 to 758 [25]. The
PCR products were gel purified and subeloned into the EcoRV
site of pBluescript II SK(—) using T-vector method [261. The
authenticity of the PCR amplified products was validated by DNA
sequencing using fluorescence-based cycle sequencing method
with Taq DNA polymerase and fluorescence DNA sequencer.
RNA extraction and Northern blot analysis
Glomerular isolation was carried out as described above. Total
RNA was extracted from isolated glomeruli of four rats in each
group by the acid guanidinium thiocyanate-phenol-chloroform
extraction method [27]. Twenty micrograms of total RNA was
subjected to electrophoresis in a 2.2 M formaldehyde-i% agarose
gel and transferred to Hybond-N nylon membranes (Amersham),
and then fixed by baking at 80°C for two hours. The membranes
were prehybridized for at least two hours at 37°C in hybridization
solution (5 X SSC, 5 X Denhardt's solution, 0.1 mg/mI of salmon
sperm DNA, 0.1% SDS, and 50% formamide). The eDNA probes
were labeled with 32P-dCTP by the random primer method and
hybridized in the hybridization solution at 42°C overnight. The
membranes were washed twice in 2 >< SSC, 0.1% SDS, and twice
in 1 X SSC, 0.1% SDS at 42°C for 15 minutes. Autoradiography
was performed by the standard methods. The autoradiographs
were scanned with a Dualwavelength flying-spot CS-9000 scanner
(Shimidzu, Tokyo, Japan) to quantitate the relative intensities of
the mRNA bands. The quantitative measurements of each mRNA
band were expressed as the ratio to that of GAPDH mRNA
bands.
Routine histological examination
Kidney tissues for light microscopy were fixed in neutral
formalin and embedded in paraffin, and 2 jim sections were
stained with periodic acid-Schiff reagent.
Immunohistochemical staining for PCNA and
monocyte-macrophages
Proliferating cell nuclear antigen (PCNA) is an auxiliary pro-
tein to DNA polymerase-, and it is expressed in nucleus strongly
in late G1 and S phases of the cell cycle [28, 29]. Therefore, PCNA
antibodies are used as tools for detecting proliferating cells. To
evaluate cell proliferation and cell infiltration, we carried out
immunohistochemical staining for PCNA and monocyte-mac-
rophages. Kidney tissues were fixed in neutral formalin and
embedded in paraffin, and 3 jim sections were mounted on
poly-L-lysine-coated slides. The sections were deparaffinized,
immersed in methanol containing 0.3% H202 for 30 minutes, and
stained for PCNA with PCIO, a mouse monoclonal IgG antibody
(Daco Corp., Santa Barbara, CA, USA) [30], or for monocyte-
macrophages with ED-i, a mouse monoclonal IgG antibody
(Serotec, Oxford, UK) [31]. As a pretreatment, sections for PC1O
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were immersed in 2 M HC1 for 30 minutes [32], or sections for
ED-i were digested with proteinase K (5 pg/mi) (Boehringer
Mannheim GmbH Biochemica, Mannheim, Germany) at 37°C for
15 minutes. Thereafter, these sections were incubated with PC10
or ED-i respectively, and subsequently processed using a strepta-
vidin-biotin immunoperoxidase method [33] with 3,3'-diamino-
benzidine (DAB) as the chromogen.
Quantitation of histological findings
For each section, 50 glomeruli were sequentially examined and
the mean numbers of following variables per glomerular cross-
section were measured: cell nuclei in periodic acid-Schiff stained
tissue sections (total cellularity), PCNA positive cells (prolifera-
tion), and ED-i positive cells (monocyte-macrophage infiltration)
determined by immunohistochemistry. Glomerular cross sections
measuring less than 80 am diameter were excluded from the
analysis.
Mirror section analysis of preproET-i mRI'JA and ED-i or OX-7
To identify the glomerular cells expressing ET-i, we carried out
a mirror section analysis of preproET-1 mRNA and cell marker
antigens [34, 35]. Kidney tissues were fixed with 4% paraformal-
dehyde in 0.1 M phosphate buffer overnight, dehydrated with
graded ethanol series and chloroform, and embedded in paraffin.
Using a mirror sectioning technique, two serial 3-.tm-thick sec-
tions were obtained with the cut surfaces facing each other, and
mounted on 2% 3-amino-propyl-triethoxysilane coated slides. All
treatments were performed in a ribonuclease free condition.
Each section was then individually reacted either with a pre-
proET-1 cRNA probe by in situ hybridization or with ED-i
antibody and OX-7 antibody by immunohistochemistry as de-
scribed below.
Double immunohistochemical staining
Kidney sections were deparaffinized, immersed in methanol
containing 0.3% H202 for 30 minutes, and digested with protein-
ase K (5 pg/mI) at 37°C for 15 minutes, and then the sections were
double immunostained for monocyte-macrophages and mesangial
cells.
First, the sections were stained for monocyte-macrophages with
ED-i, a mouse monoclonal IgU antibody, using biotinylated
rabbit anti-mouse IgG, streptavidin-immunoperoxidase, and 3,3'-
diaminobenzidine (DAB) (Nichirei Corp., Tokyo, Japan) as the
chromogen. The sections were then immersed for 1.5 hours in
glycine-hydrochioric acid buffer at pH 2.2 to elute the tissue
bound antibodies [36, 37]. Thereafter, the tissue sections were
rinsed in PBS containing 0.005% biotin for 30 minutes to block
the biotin-binding sites of remaining streptavidin [38].
Subsequently, the sections were stained for mesangial cells with
OX-7, a mouse monoclonal IgG antibody (Accurate Chemicals,
Inc., Westbury, NY, USA), using biotinylated rabbit anti-mouse
IgG, streptavidin-alkaline phosphatase, and new fuchsin
(Nichirei) as the chromogen. Activity of endogenous alkaline
phosphatase was blocked by adding 1 mivi levamisole (Sigma, St.
Louis, MO, USA) to the substrate solution [39]. The sections were
counterstained with hematoxylin. Negative controls were obtained
by omitting either of the primary antibodies.
Preparation of digoxigenin labeled riboprobes
Digoxigenin-labeled single strand RNA probes were prepared
using DIG RNA Labeling Kit (Boehringer Mannheim) according
to the manufacturer's instructions. A 2.0 kb preproET-i cDNA
fragment (provided by Dr. T. Sakurai), was subcloned into the
EcoRI site of pBluescript II SK(—) transcription vector which
contains promoters for T7 and T3 RNA polymerase (Stratagene,
La Jolla, CA, USA). This plasmid was either linearized with
restriction enzyme PstI and transcribed with T7 RNA polymerase
(GIBCO BRL) to generate an anti-sense probe, or linearized with
Hindill and transcribed with T3 RNA polymerase (Boehringer
Mannheim) to generate a sense probe. Subsequently, RNA
probes were ethanol-precipitated and subjected to alkaline diges-
tion by incubation in 40 mrvi NaHCO3 and 60 mrvi Na2CO3 at 60°C
for 10 minutes to obtain 500 bp RNA probes [40]. They were then
neutralized, ethanol-precipitated, and used for in situ hybridiza-
tion. The specificity of the 2.0 kb cDNA was assessed by Northern
blot analysis performed as described above.
In situ hybridization
Kidney sections were deparaffinized, rehydrated, and then
digested with proteinase K (5 iWml) at 37°C for 15 minutes. The
sections were refixed with 4% paraformaldehyde in 0.i M phos-
phate buffer for 15 minutes, and acetylated with 0.25% acetic
anhydride in 0.1 M triethanolamine pH 8.0 for 10 minutes. They
were dehydrated with graded ethanol series and air dried. The
hybridization solution contained 50% deionized formamide, 10
mM Tris-HCI pH 7.6, iXDenhardt's solution, 10% dextran sul-
fate, 600 mivi NaC1, 0.25% SDS, i mM EDTA pH 8.0, 200 pg/mI
of yeast tRNA, and 2.0 .tg/ml of RNA probe. Fifty microliters of
hybridization solution was applied to each section, and it was
coverslipped. Hybridization was carried out in a moist chamber
humidified by 50% formamide at 50°C for 16 hours [41]. Next, the
sections were washed in 5 X SSC briefly and in 2 X SSC containing
50% formamide for 30 minutes at 50°C. In some of the sections,
RNase A treatment (20 j.Lg/ml RNase A in 10 mM Tris-HC1 pH
8.0, 1 mi EDTA) was carried out at 37°C for 30 minutes to
exclude any false-positive readings due to mishybridization. The
sections were washed in 2 x SSC and in 0.2 x SSC for 20 minutes
twice at 50°C. Blocking was accomplished by 2% skim milk for one
hour. The sections were incubated with alkaline phosphatase-
conjugated anti-digoxigenin antibody (1:1000 dilution) (Boehr-
inger Mannheim) for 30 minutes at room temperature. After
washing in DIG 1 buffer (100 mM Tris-HC1 pH 7.5, 150 ms NaC1)
twice for 15 minutes, and in DIG 3 buffer (100 mM Tris-HC1 pH
9.5, 100 mM NaCI, 50 mivi MgCl2) for five minutes, visualization
was carried out with NBT (nitroblue tetrazolium salt), 5-bromo-
4-chloro-3-indolyl phosphate, and 1 mM levamisole in DIG 3
buffer. Controls were obtained by replacing the antisense probe
with a sense probe under the same conditions.
Statistical analysis
Data are expressed as mean SE. The statistical analysis of the
multiple groups was performed using a one-way analysis of
variance (ANOVA) with the modified t-test by Bonferroni's
method. Statistical significance was defined as P < 0.05.
Days
0 1 4 7 14
ppET-1
2.3 kb—-
ETAR
4.2 kb—-
5.0 kb — *lbet.eulNusS
GAPDH
1.3kb— 4 t
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Table 1. Total cellularity, proliferating cells, and monocyte-
macrophages in normal rats day 0 (baseline), rats with anti-Thy 1 GN
on days 1, 4, 7, and 14
Day Total cells
Proliferating cells
(PCNA+)
Monocyte-macrophages
(ED-1+)
0 47.8 1.1 0.5 0.1 1.2 0.2
1 41.0 0.6 2.6 0.5 11.9 0.4k'
4 58.1 1.3 12.0 0.2 6.0 0.2
7 62.9 0.5 7.6 0.3a 5.5 o.2a
14 60.0 1.2 2.5 0.3 2.4 0.1
Data are expressed as the mean number
cross section from eight rats in each group.
a P < 0.01 versus day 0.
SE of cells per glomerular
Days
Results
Experimental glomerulonephritis
The administration of ATS to rats produced an acute form of
mesangial proliferative glomerulonephritis as described previ-
ously [17, 421. The glomerular lesions in the early stage (on day 1)
were characterized by a decrease in total glomerular cellularity
due to complement-mediated mesangiolysis, although it was
partially offset by markedly infiltrating glomerular monocyte-
macrophages which were ED-i positive (Table 1). Such lesions
were followed by an increase in total glomerular cellularity in the
later stages (on days 4 and 7). The glomerular hypercellularity in
the later stages was considered to be mainly due to proliferating
cells which were PCNA positive (Table 1).
Glomerular production of ET-1 protein
After a 24-hour incubation, ET-1 production in isolated gb-
meruli from normal rats (day 0) was invariably low. ET-1 produc-
tion in isolated glomeruli from rats with anti-Thy 1 GN increased
slightly on day 1, and further increased significantly on days 4 and
7, being maximal on day 7 (5.3-fold greater than the baseline
level), and then decreased on day 14 after disease induction (Fig.
1). The level of ET-1 production in glomeruli from rats with
anti-Thy 1 GN changed in concordance with the glomerular cell
proliferation.
Glomerular expression of preproET-1 and ET receptors mRNA
Expression of the 2.3 kb preproET-1, 4.2 kb ETA receptor, and
5.0 kb ET receptor mRNA transcripts could be detected in
glomerular RNA from normal rats (day 0) (Fig. 2). The level of
preproET-1 mRNA increased significantly on days 1, 4, 7, and 14
after ATS administration, being maximal on day 4 (4.5-fold
greater than the baseline level; Fig. 3A). The level changed in
concordance with the glomerular cell proliferation. The level of
ETA receptor mRNA decreased significantly on day 1, then
increased significantly on days 4 and 7, being maximal on day 7
(5.2-fold greater than the baseline level), and then returned to the
baseline level on day 14 (Fig. 3B). The level of ETB receptor
mRNA decreased significantly on days 1, 4, and 7, and then
returned to the baseline level on day 14 (Fig. 3C). The level of
GAPDH mRNA did not change significantly during the disease
process.
Effect of ETA receptor antagonist on glomerular cell proliferation
The glomeruli of saline-treated rats with anti-Thy 1 GN showed
a marked increase in total cellularity on days 4 and 7 (Fig. 4A). In
contrast, the glomeruli of FR139317-treated rats showed a signif-
icantly smaller increase in total cellularity than that of saline-
treated rats on days 4 and 7, respectively (Fig. 4B) (Table 2). The
number of proliferating cells (that is, PCNA positive cells) in
glomeruli of FR139317-treated rats was significantly smaller than
that of saline-treated rats on days 4 and 7, respectively (Table 2).
Therefore, the inhibition of increase in total glomerular cellularity
could have been caused by the reduction in glomerular cell
proliferation. No significant differences in body weight or kidney
weight were observed between saline- and FR139317-treated rats
Fig. 2. Northern blot analysis of preproET-1 (ppET-1), ETA receptor
(ETAR), and ETB receptor (ETBR) mRNA in glomendi of normal rats day 0
(baseline), rats with anti-Thy 1 GN on days 1, 4, 7, and 14. Total RNA was
separated on a 1% agarose gel (20 .rg/1ane) and probed with 32P-labeled
eDNA. The same results were obtained in four different experiments.
Time, days
Fig. 1. ET-1 production in isolated glomeruli of normal rats day 0 (base-
line), rats with anti-Thy 1 GNon days 1, 4, 7, and 14. Data are expressed as
means SE for five separate experiments. *P < 0.05 versus day 0. <
0.01 versus day 0.
0 1 4 7 14
Cl) 4
.0
Fig. 3. Quantitative analysis ofpreproET-1 (A), ET4 receptor (B), and ETB
receptor (C) mRNA in glomeruli of normal rats day 0 (baseline), rats with
anti-Thy 1 GN on days 1, 4, 7, and 14. The relative intensity of the
autoradiographic signals was quantitated and calculated as the ratio of
each mRNA to GAPDH mRNA, and then expressed as degree of change
relative to baseline levels. 'P < 0.05 versus day 0. * *p < 0.01 versus day 0.
Fig. 4. Comparison of histological findings in glomeruli of rats with mesan-
gial proliferative glomerulonephritis on day 7. A. The glomeruli of saline-
treated rats show marked hypercellularity. B. The glomeruli of FR139317-
treated rats show significantly less cellularity than that of saline-treated
rats. (Periodic acid-Schiff reagent with hematoxylin counterstain, X400).
A
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Cl)
C
.0
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C
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Time, days
1
1
0.5
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on the day of sacrifice. Systolic blood pressure values did not
change significantly from the baseline levels in either saline- or
FR139317-treated rats, and also showed no significant differences
between either group on days 0, 4, and 7 (Table 3).
Detection of preproET-1 mRNA by in situ hybridization
In normal rats (day 0), preproET-1 mRNA expression was
0 1 4 7 14 detected in glomeruli, endothelial cells of vessels, and collectingducts. Glomerular preproET-1 mRNA expression was detectable
Time, days mainly in endothelial and mesangial regions, but the level of
mRNA was low (Fig. 5A). In rats with anti-Thy 1 GN, an increase
in glomerular expression of preproET-1 mRNA was observed.
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Table 2. Effect of FR139317 on total cellularity and proliferating cells
io rats with anti-Thy 1 UN
cells
Proliferating cells
(PCNA+)
Day 0 47.8 1.1 0.5 0.1
Day 4
Cootrol 58.0 1.0 12.8 0.3
FR139317 49.6 1.? 5.9 0.4
Day 7
Control 63.8 1.2 8.3 0.6
FR139317 52.4 l.0' 4.2 o.3
Data are expressed as the mean number SE of cells per glomerular
cross section from eight rats in each group. For comparison, data from
normal rats day 0 are shown as the baseline level.
ap < 0.01 vs. control (saline-treated rats)
hP C 0.01 vs. day 0
The level of preproET-1 mRNA on day 4 (Fig. 5 C, D) was much
higher than that on day I in glomeruli (Fig. SB). The cells
expressing strongly preproET-1 mRNA localized to hypercellular
regions in glomeruli. These results were consistent with the results
of Northern blot analysis in glomeruli. A control experiment with
a sense probe did not show any staining of tissue (Fig. SE).
Identification of the cell type expressing ET-1
To determine the cellular localization of glomerular pre-
proET-i mRNA, we carried out double immunolabeling for
monocyte-macrophages with ED-i and for mesangial cells with
OX-7 in the mirror image sections of in situ hybridization.
On day 1, marked glomerular monocyte-macrophage infiltra-
tion, which was scattered in normal glomeruli, was noted, but
mesangial cell staining was weak. In this early stage, mirror
section analysis revealed that the cells expressing preproET-I
mRNA were mainly infiltrating monocyte-macrophages, and
partly mesangial cells (Fig. SF).
On day 4, glomerular monocyte-macrophage infiltration de-
creased, on the other hand, marked mesangial cell proliferation
was noted. In this later stage, mirror section analysis revealed that
mesangial cells replaced monocyte-macrophages as the main cells
expressing preproET-i mRNA (Fig. SG). The hypercellular re-
gions were occupied by mesangial cells expressing preproET-1
mRNA, while monocyte-macrophages continued to express pre-
proET-i mRNA (Fig. SH).
Discussion
The main question addressed by the present study was whether
ET-i functions as a mitogen for mesangial cells in vivo. The
present study shows that ET-1 is a potent mitogen for mesangial
cells in the experimental mesangial proliferative glomerulonephri-
tis. Northern blot analysis of glomerular RNA demonstrated a
marked increase in preproET-1 mRNA transcript in rats with
experimental glomerulonephritis. In addition, ET-1 production in
isolated glomeruli also increased markedly in rats with glomeru-
lonephritis. Furthermore, these increases were concordant with
the glomerular cell proliferation. Since most of the proliferating
cells have been shown to be mesangial cells in this model [43—45],
ET-i gene and protein expression are considered to change in
concordance with the mesangial cell proliferation.
Recent studies have revealed that ET-i is a potent mitogen for
mesangial cells in vitro [14, 15], and this mitogenesis is thought to
Table 3. Effect of FR139317 on body weight (wt), kidney weight (wt),
and the time course of systolic blood pressure (SBP)
Day Control FR139317
Body wt g 7 257.5 9.0 250.0 8.2
Kidney wt g 7 1.02 0.08 0.96 0.07
SBP mm Hg 0
4
7
146.5 1.1
150.6 4.6
146.6 4.1
144.0 1.1
149.5 3.3
145.1 1.4
Data are expressed as means 5E from eight rats in each group. No
significant differences were observed between control and FR139317
groups.
be mediated by ETA receptor [46], while mesangial cells have both
ETA and ETB receptor [47—49]. Therefore, to confirm the mito-
genie function of ET-1 in vivo, we administered a specific ETA
receptor antagonist, FR139317, to rats with experimental glomer-
ulonephritis, and performed histological evaluation of renal tis-
sues after disease induction. As a result, FR139317 significantly
reduced glomerular cell proliferation as compared to control.
Previous studies demonstrated that another ETA receptor antag-
onist, B0123, inhibits ET-1-induced 3H-thymidine uptake in
vascular smooth muscle cells [50, 51], and FR139317 reduces
proliferation of mesangial cells in a model of progressive nephron
loss in rats [52] or lupus nephritis in mice [53]. These data strongly
support our results. FR139317 did not affect the nutritional
condition or systolic blood pressure during the disease process. In
the previous report, B0123 did not affect systemic or renal
hemodynamics in normotensive rats [54]. Since rats with anti-Thy
1 UN are usually normotensive, the inhibitory effects of FR139317
on cell proliferation would probably not be due to any indirect
effects through antihypertensive actions but be due to the direct
effects of antagonizing ETA receptor. Taken together with the
findings of ET-1 gene and protein expression, our data on ETA
receptor blocking provide convincing evidence that ET-1 func-
tions as a potent mitogen for mesangial cells in experimental
glomerulonephritis and the mitogenesis is mediated by ETA
receptor at least in part.
The other question addressed by the present study was which
glomerular cells mainly produce ET-1 in this model. To answer
this question, we carried out a mirror section analysis of pre-
proET-1 mRNA and cell marker antigens. Our results show that
the principal cells expressing preproET-1 mRNA are infiltrating
monocyte-macrophages in the early stage, and they are replaced
by mesangial cells in the later stage. These results could be
interpreted as follows. In the early destructive stage (1 hr to 2
days), most mesangial cells are injured and functionally damaged
[17j. Therefore, infiltrating monocyte-macrophages, a rich source
of cytokines, might play an important role for initiating mesangial
cell proliferation in a paracrine fashion by releasing ET-1. It is
supported by recent in vivo and in vitro reports that monocyte-
macrophages could produce and release ET-1 [55, 56]. In the later
proliferative stage (4 to 14 days), ET-1 released from monocyte-
macrophages might decrease as they left from glomeruli, and then
mesangial cells might become a major source of ET-1 production,
which could induce a subsequent proliferation of mesangial cells
in an autocrine fashion.
Although the present data demonstrated an increase in glomer-
ular ET-1 expression and detected the source of ET-1 in experi-
mental glomerulonephritis, the mechanism of ET-1 overexpres-
sion remains unclear. Recent studies have demonstrated the
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Fig. S. In situ hybridization for the preproET- I mRNA (A-E) and double-immunolabeling with ED-i and OX-7 (F-H) in normal rats and rats with mesangial
proliferative glomerulonephritis. (B) and (F) arc mirror image sections on day 1, while (C) and (G), (D) and (H) arc mirror image sections on day 4. In
normal rats, preproET-1 mRNA is expressed in endothelial cells and mesangial cells in glomcruli, endothelial cells of small arteries (arrow), and
endothelial cells in arterioles (arrowhead) (A). On day 1 after disease induction, increased expression of glomerular preproET-1 mRNA is observed (B).
On day 4, expression of glumerular preproET-i mRNA becomes strongly positive and localizes to hyperccllular regions (C, D). Hybridization with a
sense probe shows no staining of glomeruli or vessels on day 4 (E). Double-immunolabcling in the mirror image section on day 1 shows that the cells
expressing preproET-i mRNA are mainly ED-i positive (brown; arrows) and partly OX-7 positive (bright red; arrowheads) (F). On day 4, the cells
expressing prepruET-1 mRNA are mainly OX-7 positive (bright red) (0), while some of the cells expressing preproET-1 mRNA are ED-i positive
(brown; arrows) (H) (X400).
importance of mediators derived from platelets or monocyte-
macrophages for glomerular cell proliferation in renal diseases
[57, 58]. Like monocyte-macrophages, platelets contain many
mediators including thrombin, interleukin-1, TGF-f3, and PDGF
[59, 60], which could be released in glomeruli after glomerular
injury. Indeed, increased glomerular expression of TGF-f3 [61] or
PDGF [62] was shown in rats with experimental glomerulonephri-
tis. In addition, recent in vitro studies have revealed that ET-1
production in mesangial cells is triggered by these mediators [63,
64]. Thus, these mediators derived from platelets or monocyte-
macrophages could contribute to the increase of ET-1 expression
in mesangial cells in the later stage. Finally, released ET-i could
exert a proliferative effect on mesangial cells in an autocrine
fashion in combination with thcse mediators.
The results of mirror section analysis that the main cells
expressing ET-1 varied with the different stages might explain the
discrepancy in the expression level between preproET-1 and ET
receptors mRNA. It was previously shown that ETA receptor
expression was localized to mesangial cells, and that ETB receptor
expression was localized to endothelial cells and mesangial cells in
normal glomeruli [5]. In the early stage (day 1), most mesangial
cells are damaged as described above, so that the decreased
expression of ETA and ETB receptor in this stage could be related
to the damage of receptor source cells, that is, mesangial cells. On
the other hand, the increased expression of ET-i could be
explained by infiltrating monocyte-macrophages instead of dam-
aged mesangial cells as shown by mirror section analysis. In
contrast, it is still controversial whether monocyte-macrophages
have the ET receptors. There have been a few previous reports
about ET receptors of monocyte-macrophages [55, 65, 66], but the
findings of these reports differ greatly regarding the existence or
the character of this receptor. At least according to our results, it
appears that glomerular infiltrating monocyte-macrophages did
not express ET receptors, because the decreased expression of ET
receptors should be offset by monocyte-macrophages to some
extent if they expressed either ETA or ET receptor. In short, the
early accumulation of monocyte-macrophages in glomeruli could
explain the increased expression of preproET-i mRNA in spite of
the decreased expression of ET receptor mRNA in the early stage.
In the later stages (days 4 and 7), ETA receptor expression
increased, while ETB receptor expression remained decreased,
and then both receptors expression returned to each baseline level
on day 14. The mechanisms how both receptors showed different
expression patterns in this stage are still unclear, but the antipro-
liferative effects of ETA receptor antagonist indicate that the
increased ETA receptor expression contributes to the amplifica-
tion of mesangial cell response to ET-1, and finally to subsequent
mesangial cell proliferation. In contrast, the consistent decrease
of ETB receptor expression may prevent overexpression of ET-1,
and thus might possibly contribute to the self-limiting course of
anti-Thy 1 ON, because ET-1 increases its own synthesis through
ETB receptor [67]. Very little remains known about the regulation
of ET receptor expression in any tissue, and further studies are
still needed to clarify the mechanisms.
In conclusion, the present study provides direct in vivo evidence
that ET-1 functions as a mitogen in mesangial proliferative
glomerulonephritis, and that ET-1 acts for mesangial cells in a
paracrine fashion during the early stage and in an autocrine
fashion during the later stage.
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